There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

The following is a summary of “Dupilumab Improves Urticaria-Specific Quality of Life in Patients with Chronic Spontaneous ...

Dupilumab improved exacerbations and lung function in patients with COPD and T2 inflammation, regardless of baseline BODE index score.

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely ...

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely monitored for its onset.

Combining Deep Pruritus Relief, Effective Skin Clearance, and a Well-tolerated Safety ProfileHONG KONG, Apr 9, 2025 - (ACN Newswire) - SinoMab BioScience ...

Patients with early-onset atopic dermatitis, especially those with severe atopic dermatitis, are more likely to develop pediatric uveitis.

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

A cohort study finds children with early-onset atopic dermatitis to be at increased risk for uveitis, highlighting a need for ophthalmologic monitoring in youth.